[
  {
    "ts": "2026-01-20T01:25:04+00:00",
    "headline": "CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Dividend Kings to Buy in 2026. On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA (lumateperone), when used alongside an antidepressant, delivered significantly higher remission rates in adults with major depressive disorder compared with […]",
    "url": "https://finance.yahoo.com/news/caplyta-shows-stronger-remission-results-012504612.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "70203d5d-85f9-32b3-82d4-386112d5ee3c",
      "content": {
        "id": "70203d5d-85f9-32b3-82d4-386112d5ee3c",
        "contentType": "STORY",
        "title": "CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Dividend Kings to Buy in 2026. On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA (lumateperone), when used alongside an antidepressant, delivered significantly higher remission rates in adults with major depressive disorder compared with […]",
        "pubDate": "2026-01-20T01:25:04Z",
        "displayTime": "2026-01-20T01:25:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/caplyta-shows-stronger-remission-results-012504612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/caplyta-shows-stronger-remission-results-012504612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]